Breast Surgery — MCQs

A 35-year-old female patient presents with a hard nodule approximately 1 cm in diameter, located slightly above and lateral to her right areola. A dye is injected into the tissue around the tumor, and lymphatic vessels draining the area are exposed by incision. These vessels, which uptake the visible dye, are traced to surgically expose the lymph nodes receiving lymph from the tumor. Which of the following lymph nodes will most likely first receive lymph drainage from this tumor?

Q97Medium

Adjuvant therapy after mastectomy is needed in all of the following situations except:

Q98Medium

A 30-year-old female underwent lumpectomy for a 1.2x1 cm breast lesion with positive axillary nodes. She received adjuvant radiotherapy, tamoxifen, and chemotherapy. What is the recommended line of management for her follow-up?

Q99Easy

Which of the following is considered a bad prognostic sign for carcinoma of the breast?

Q100Easy

Which of the following is not a risk factor for breast carcinoma?

Breast Surgery Indian Medical PG Practice Questions and MCQs

Question 91: In a patient with carcinoma breast stage T4b, as per TNM classification, what defines this stage?

A. Nipple retraction (Correct Answer)
B. Skin ulcer over the swelling
C. Dermal edema
D. Satellite nodules

Explanation: In the AJCC TNM staging of breast cancer, **T4** represents a tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). Specifically, **T4b** is defined by clinical evidence of skin involvement that does not meet the criteria for inflammatory carcinoma (T4d). ### Why Nipple Retraction is the Correct Answer In the context of this specific question format (often seen in standard surgical textbooks like Bailey & Love), **T4b** is characterized by skin changes such as **ulceration, satellite skin nodules, or edema (including peau d'orange)**. However, it is a common high-yield distinction that **nipple retraction**, skin dimpling, or attachment to the skin without actual ulceration or edema does **not** upgrade a tumor to T4; these are considered features of the primary tumor (T1-T3) based on size. *Note: There appears to be a discrepancy in the provided key versus standard AJCC 8th edition guidelines. In standard TNM, Nipple Retraction is NOT T4b; however, in many PG entrance exams, this question tests the "Skin Involvement" criteria where Nipple Retraction is often the "except" or the specific distractor.* ### Analysis of Options * **B, C, and D (Skin ulcer, Dermal edema, Satellite nodules):** These are the classic definitions of **T4b**. Dermal edema (Peau d'orange) and skin ulceration signify advanced local spread. * **A (Nipple Retraction):** This occurs due to the shortening of Galactophorous ducts. While a sign of malignancy, it does not qualify as T4b unless accompanied by the skin changes mentioned above. ### High-Yield Clinical Pearls for NEET-PG * **T4a:** Extension to the **chest wall** (Serratus anterior, ribs, intercostal muscles). Note: Involvement of the Pectoralis major alone is NOT T4a. * **T4c:** Presence of both T4a and T4b features. * **T4d:** **Inflammatory carcinoma** (characterized by diffuse erythema and edema involving >1/3 of the breast). * **Peau d'orange:** Caused by cutaneous lymphatic obstruction, leading to dermal edema where the hair follicles remain tethered, creating an orange-peel appearance.

Question 92: In a post-mastectomy patient, the suction drain is accidentally removed on the 2nd post-operative day, and the patient presents with oozing and swelling in the chest. What is the next best step in management?

A. Open incision and pack with saline gauze
B. Aspiration under aseptic conditions and apply pressure dressing (Correct Answer)
C. Reinsert the drain
D. Wait and watch

Explanation: ### **Explanation** The clinical presentation of swelling and oozing following the premature removal of a post-mastectomy drain is classic for a **Seroma**. A seroma is a sterile collection of serous fluid in the dead space created by the elevation of skin flaps during surgery. **1. Why Option B is Correct:** The primary goal in managing a symptomatic seroma is to evacuate the fluid to prevent skin flap necrosis and reduce the risk of secondary infection. **Aspiration under aseptic conditions** is the standard initial treatment. Following aspiration, a **pressure dressing** is applied to obliterate the dead space and prevent the fluid from re-accumulating. This approach is minimally invasive and highly effective for early-stage collections. **2. Why Other Options are Incorrect:** * **Option A (Open incision):** This is contraindicated for a simple seroma as it converts a sterile collection into an open wound, significantly increasing the risk of infection and delayed wound healing. * **Option C (Reinsert the drain):** Reinserting a drain through the original site or a new stab wound is generally avoided due to the high risk of introducing bacteria into the surgical site. It is only considered if the seroma is massive or recurrent after multiple aspirations. * **Option D (Wait and watch):** While small, asymptomatic seromas may resolve spontaneously, a patient with active oozing and swelling requires intervention to prevent complications like wound dehiscence or infection. ### **High-Yield Clinical Pearls for NEET-PG** * **Most common complication** after mastectomy/axillary lymph node dissection (ALND): **Seroma formation.** * **Dead Space Management:** The use of suction drains (e.g., Romo Vac) is the most effective way to prevent seroma by keeping the skin flaps adherent to the chest wall. * **Drain Removal Criteria:** Drains are typically removed when the output is **<30 ml in 24 hours** (usually by the 5th–10th day). * **Nerve Injuries in Mastectomy:** * **Long Thoracic Nerve (Bell’s):** Winging of Scapula (Serratus Anterior). * **Thoracodorsal Nerve:** Weakness in adduction/internal rotation (Latissimus Dorsi). * **Intercostobrachial Nerve:** Most commonly injured; causes numbness in the inner aspect of the upper arm.

Question 93: Which of the following statements is true with respect to discharge of blood from the nipple, EXCEPT?

A. It is occasionally normal (Correct Answer)
B. Suggests duct papilloma
C. Suggests carcinoma breast
D. Always needs further evaluation

Explanation: ### Explanation **Core Concept:** Nipple discharge is a common clinical presentation in breast surgery. The key to answering this question lies in distinguishing between **pathological** and **physiological** discharge. **Bloody (sanguineous) nipple discharge is never considered normal.** It is always a pathological sign that mandates a thorough investigation to rule out malignancy. **Why Option A is the Correct Answer (The "Except" Statement):** Bloody discharge is **never "occasionally normal."** While milky discharge (galactorrhea) or greenish/brownish discharge (duct ectasia) can sometimes be physiological or related to benign hormonal changes, the presence of blood indicates an underlying lesion (either benign or malignant) that has eroded the ductal lining. **Analysis of Incorrect Options:** * **B. Suggests duct papilloma:** This is the **most common cause** of spontaneous, single-duct bloody nipple discharge. It is a benign epithelial growth within the duct. * **C. Suggests carcinoma breast:** In approximately 5–15% of cases, bloody nipple discharge is the presenting symptom of malignancy, most commonly **Ductal Carcinoma In Situ (DCIS)** or invasive papillary carcinoma. * **D. Always needs further evaluation:** Because of the risk of malignancy, any patient presenting with bloody discharge must undergo the "Triple Assessment" (Clinical examination, Imaging like Mammography/Ultrasound, and Cytology/Biopsy). **NEET-PG High-Yield Pearls:** * **Most common cause of bloody nipple discharge:** Intraductal Papilloma. * **Most common cause of nipple discharge overall:** Duct Ectasia (usually multicolored/sticky). * **Investigation of Choice:** For a specific leaking duct, **Microdochectomy** (excision of the single involved duct) is both diagnostic and therapeutic. * **Risk Factor:** Bloody discharge in a post-menopausal woman or associated with a palpable mass significantly increases the suspicion of breast cancer.

Question 94: Inflammatory carcinoma is classified under which TNM staging category?

A. T4a
B. T4b
C. T4c
D. T4d (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. T4d** **Medical Concept:** Inflammatory Breast Cancer (IBC) is a distinct, highly aggressive clinical entity characterized by rapid onset of erythema, edema (peau d'orange), and warmth involving at least one-third of the breast. In the TNM staging system (AJCC 8th Edition), IBC is specifically categorized as **T4d**. This classification is based on **clinical findings** rather than purely pathological ones, as the hallmark "dermal lymphatic invasion" by tumor emboli is not required for the diagnosis if the clinical criteria are met. **Analysis of Incorrect Options:** * **T4a:** Refers to tumor extension to the **chest wall** (involvement of ribs, intercostal muscles, or serratus anterior; pectoralis muscle involvement alone does not qualify). * **T4b:** Refers to **skin changes** such as edema (including peau d'orange), ulceration, or satellite skin nodules, but these do *not* meet the criteria for inflammatory carcinoma (i.e., they involve less than one-third of the breast). * **T4c:** Represents a combination of both **T4a and T4b** (extension to chest wall plus skin ulceration/edema). **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Diagnosis:** IBC is primarily a clinical diagnosis. The classic **"Peau d'orange"** appearance is due to the obstruction of dermal lymphatics by tumor emboli. * **Staging:** All T4d tumors are automatically classified as at least **Stage IIIB**, regardless of nodal status (if N0). * **Management:** The standard of care is **Multimodality Therapy**: Neoadjuvant Chemotherapy (NACT) followed by Modified Radical Mastectomy (MRM) and Radiotherapy. *Never* start with primary surgery. * **Differential Diagnosis:** Must be differentiated from acute mastitis; if a suspected "breast infection" does not respond to antibiotics within 1–2 weeks, a biopsy is mandatory to rule out IBC.

Question 95: What is the general trend of the incidence of breast cancer with increasing age?

A. Increases with increasing age (Correct Answer)
B. Has declined significantly since the 1940s
C. Is directly related to dietary fat intake
D. Is directly related to coffee intake

Explanation: **Explanation:** **1. Why Option A is Correct:** The single most significant risk factor for breast cancer is **increasing age**. The incidence follows a linear progression: it is rare before age 25, increases rapidly after age 30, and continues to rise throughout a woman’s lifetime, peaking in the 6th and 7th decades. This is primarily due to the cumulative exposure of breast tissue to endogenous hormones (estrogen/progesterone) and the time-dependent accumulation of genetic mutations in mammary epithelial cells. **2. Why Other Options are Incorrect:** * **Option B:** The incidence has **not declined**; rather, it has increased since the 1940s due to better screening (mammography), changes in reproductive patterns (later first pregnancy, nulliparity), and increased life expectancy. * **Option C:** While obesity (especially post-menopausal) is a known risk factor due to peripheral conversion of androstenedione to estrone in adipose tissue, a **direct causal link** between specific dietary fat intake and breast cancer remains controversial and is not the "general trend" of incidence. * **Option D:** There is no established scientific evidence linking coffee intake to an increased risk of breast cancer. In fact, some studies suggest caffeine may have a protective effect or no effect at all. **Clinical Pearls for NEET-PG:** * **Most common site:** Upper Outer Quadrant (45-50%). * **Protective factors:** Early pregnancy (<20 years), breastfeeding, and late menarche. * **Gail Model:** The most commonly used tool to estimate the individualized risk of developing breast cancer. * **High-Yield Fact:** In India, breast cancer has overtaken cervical cancer to become the most common cancer among women in urban populations, with a trend toward affecting a younger age group compared to Western countries.

Question 96: A 35-year-old female patient presents with a hard nodule approximately 1 cm in diameter, located slightly above and lateral to her right areola. A dye is injected into the tissue around the tumor, and lymphatic vessels draining the area are exposed by incision. These vessels, which uptake the visible dye, are traced to surgically expose the lymph nodes receiving lymph from the tumor. Which of the following lymph nodes will most likely first receive lymph drainage from this tumor?

A. Anterior axillary (pectoral) nodes (Correct Answer)
B. Rotter interpectoral nodes
C. Parasternal nodes along the internal thoracic artery and vein
D. Central axillary nodes

Explanation: ### Explanation **1. Why the Correct Answer is Right:** The breast's lymphatic drainage follows a predictable pattern. Approximately **75% of the lymph** from the breast, particularly from the lateral quadrants (where this 1 cm nodule is located), drains into the **axillary lymph nodes**. The axillary nodes are organized into five main groups. The **Anterior (Pectoral) nodes** are the primary recipients of lymph from the majority of the breast tissue. They are located along the lower border of the pectoralis minor, deep to the pectoralis major. In the context of a **Sentinel Lymph Node Biopsy (SLNB)**—which is what the dye injection described in the question represents—the anterior group is typically the first "station" or Level I node to receive drainage before the lymph moves deeper into the axilla. **2. Why the Incorrect Options are Wrong:** * **B. Rotter interpectoral nodes:** These are located between the pectoralis major and minor muscles. While they do receive direct drainage from the posterior aspect of the breast, they are not the primary or most common first-line drainage site compared to the anterior axillary nodes. * **C. Parasternal nodes:** These nodes (along the internal mammary artery) drain about 20-25% of the breast lymph, primarily from the **medial quadrants**. Since the tumor is lateral to the areola, drainage to the axilla is far more likely. * **D. Central axillary nodes:** These are Level II nodes. They receive lymph from the anterior, posterior, and lateral groups. They are a "second station" and would not typically be the *first* to receive dye. **3. Clinical Pearls for NEET-PG:** * **Berg’s Levels of Axillary Nodes:** * **Level I:** Lateral to pectoralis minor (Anterior, Posterior, Lateral groups). * **Level II:** Deep to pectoralis minor (Central, Rotter’s nodes). * **Level III:** Medial/Superior to pectoralis minor (Apical nodes). * **Sentinel Lymph Node (SLN):** Defined as the first node(s) in the lymphatic basin that receives drainage from the primary tumor. * **Standard of Care:** SLNB is indicated for clinically node-negative (cN0) early breast cancer to avoid the morbidity of Axillary Lymph Node Dissection (ALND).

Question 97: Adjuvant therapy after mastectomy is needed in all of the following situations except:

A. High risk, node positive
B. Low risk, no node (Correct Answer)
C. Estrogen receptor/Progesterone receptor negative
D. Her-2-neu positive

Explanation: **Explanation:** The decision to initiate adjuvant therapy (chemotherapy, hormonal therapy, or radiotherapy) after a mastectomy is based on the risk of systemic recurrence and the biological profile of the tumor. **Why "Low risk, no node" is the correct answer:** Adjuvant therapy is generally withheld in patients with **low-risk, node-negative (N0)** disease. This typically includes patients with small tumors (usually <0.5 cm or T1a), favorable histological subtypes (e.g., tubular or mucinous carcinoma), and strongly hormone-receptor-positive status with a low proliferative index (Ki-67). In these cases, the risk of recurrence is so low that the potential toxicities of chemotherapy outweigh the marginal clinical benefit. **Analysis of Incorrect Options:** * **High risk, node positive:** Presence of even a single positive lymph node (N1 or higher) significantly increases the risk of systemic spread, making adjuvant systemic therapy (usually chemotherapy) mandatory. * **ER/PR negative:** Tumors that lack hormone receptors do not respond to endocrine therapy (like Tamoxifen). Because these "Triple Negative" or "Basal-like" cancers are more aggressive, adjuvant chemotherapy is indicated even for relatively small tumors. * **Her-2-neu positive:** Overexpression of the HER2 protein signifies an aggressive phenotype. These patients require adjuvant chemotherapy combined with targeted therapy (e.g., Trastuzumab) to improve survival outcomes. **Clinical Pearls for NEET-PG:** * **Sentinel Lymph Node Biopsy (SLNB):** The gold standard for axillary staging in clinically N0 patients to determine the need for adjuvant therapy. * **Oncotype DX:** A genomic assay used specifically in ER+, HER2-, node-negative patients to decide if chemotherapy can be safely omitted. * **Radiotherapy after Mastectomy (PMRT):** Indicated if the tumor is >5 cm (T3), involves the chest wall/skin (T4), or if there are ≥4 positive nodes.

Question 98: A 30-year-old female underwent lumpectomy for a 1.2x1 cm breast lesion with positive axillary nodes. She received adjuvant radiotherapy, tamoxifen, and chemotherapy. What is the recommended line of management for her follow-up?

A. Yearly bone scans
B. Examination once every 3 months for one year, followed by yearly mammograms (Correct Answer)
C. Liver function tests every 6 months
D. Follow-up by tumor markers every 6 months

Explanation: **Explanation:** The primary goal of follow-up after breast cancer treatment is the early detection of local recurrence or a new primary tumor in the contralateral breast, as these are potentially curable. **Why Option B is correct:** According to standard oncological guidelines (ASCO/NCCN), follow-up for a patient who has undergone breast-conserving surgery (lumpectomy) involves: 1. **Clinical Examination:** Performed every 3–6 months for the first 3 years, every 6–12 months for the next 2 years, and annually thereafter. 2. **Imaging:** A surveillance mammogram is recommended 6–12 months after the completion of radiotherapy, followed by **yearly mammograms**. Since the patient is young (30 years), clinical vigilance is high due to the risk of recurrence. **Why other options are incorrect:** * **Options A, C, and D:** Routine laboratory tests (CBC, LFTs), tumor markers (CEA, CA 15-3), and imaging for distant metastasis (Bone scans, CT, Ultrasound of the liver) are **not recommended** in asymptomatic patients. Studies have shown that intensive surveillance with these tests does not improve survival or quality of life compared to clinical follow-up and mammography. They are only indicated if the patient develops specific symptoms suggesting metastasis. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site of distant metastasis:** Bone. * **Most common site of visceral metastasis:** Lungs. * **Tamoxifen Follow-up:** Patients on Tamoxifen should have annual gynecological exams to monitor for endometrial hyperplasia/cancer. * **Mammography Timing:** The first post-treatment mammogram should not be done earlier than 6 months after radiotherapy to avoid diagnostic confusion from radiation-induced skin thickening and edema.

Question 99: Which of the following is considered a bad prognostic sign for carcinoma of the breast?

A. HER2 receptor (Correct Answer)
B. Progesterone receptor
C. Estrogen receptor
D. None of the above

Explanation: In breast carcinoma, prognosis is determined by clinical, pathological, and molecular markers. The status of hormone receptors (ER, PR) and growth factor receptors (HER2/neu) is critical for predicting both the aggressiveness of the tumor and the response to therapy. **Why HER2 receptor is the correct answer:** The **HER2/neu (Human Epidermal Growth Factor Receptor 2)** is a proto-oncogene. Its overexpression (found in 15-20% of breast cancers) leads to increased cell proliferation and survival. Clinically, HER2-positive status is associated with a **more aggressive tumor phenotype**, higher grade, increased risk of recurrence, and overall poorer prognosis compared to hormone receptor-positive tumors. While targeted therapies like Trastuzumab have improved outcomes, it remains a marker of high biological aggression. **Why the other options are incorrect:** * **Estrogen Receptor (ER) and Progesterone Receptor (PR):** These are **good prognostic markers**. Their presence indicates that the tumor is well-differentiated and "hormone-dependent." Patients with ER/PR-positive tumors generally have a slower disease progression and a favorable response to endocrine therapies (e.g., Tamoxifen or Aromatase Inhibitors). **High-Yield Clinical Pearls for NEET-PG:** * **Triple Negative Breast Cancer (TNBC):** Lacks ER, PR, and HER2. It has the worst prognosis among all molecular subtypes. * **Luminal A:** (ER/PR+, HER2-) has the best prognosis. * **Nottingham Prognostic Index (NPI):** Uses tumor size, lymph node status, and histological grade to predict survival. * **Most important prognostic factor:** Axillary lymph node status (number of nodes involved). * **Most important predictive factor:** Receptor status (determines response to specific drugs).

Question 100: Which of the following is not a risk factor for breast carcinoma?

A. Saturated fatty acids
B. Early menopause (Correct Answer)
C. Nulliparous women
D. Estrogen unopposed by progesterone

Explanation: **Explanation:** The risk of breast carcinoma is primarily linked to the **cumulative lifetime exposure of breast tissue to estrogen**. Estrogen promotes the proliferation of mammary epithelial cells, increasing the likelihood of DNA mutations. **Why Early Menopause is the Correct Answer:** Early menopause (cessation of menstruation before age 45) is actually a **protective factor**, not a risk factor. It shortens the duration of the "estrogen window," thereby reducing the total lifetime exposure to ovarian hormones. Conversely, **late menopause** (after age 55) is a well-known risk factor. **Analysis of Incorrect Options:** * **Saturated Fatty Acids:** High dietary intake of saturated fats and obesity (especially post-menopausal) are linked to increased risk. In obese women, peripheral conversion of androstenedione to estrone in adipose tissue increases circulating estrogen levels. * **Nulliparous Women:** Women who have never carried a pregnancy to term have higher risk because they do not experience the hormonal "break" provided by pregnancy and lactation. Early first pregnancy (before age 20) is protective. * **Estrogen Unopposed by Progesterone:** Prolonged exposure to estrogen without the balancing effect of progesterone (e.g., Hormone Replacement Therapy or early menarche) stimulates ductal hyperplasia, increasing malignancy risk. **High-Yield Clinical Pearls for NEET-PG:** * **The "Estrogen Window" Concept:** Risk increases with early menarche (<12 years) and late menopause (>55 years). * **BRCA Mutations:** BRCA1 (Chromosome 17) and BRCA2 (Chromosome 13) are the most significant genetic risk factors. * **Breastfeeding:** For every 12 months of breastfeeding, the relative risk of breast cancer decreases by approximately 4.3%. * **Atypical Hyperplasia:** Finding atypical ductal or lobular hyperplasia on biopsy increases risk by 4–5 times.

Practice by Chapter

Breast Anatomy and Physiology

Practice Questions

Benign Breast Diseases

Practice Questions

Breast Cancer Screening

Practice Questions

Breast Cancer: Diagnosis and Staging

Practice Questions

Surgical Management of Breast Cancer

Practice Questions

Oncoplastic Breast Surgery

Practice Questions

Sentinel Lymph Node Biopsy

Practice Questions

Axillary Surgery

Practice Questions

Breast Reconstruction Techniques

Practice Questions

Male Breast Disorders

Practice Questions

Phyllodes Tumors

Practice Questions

Management of Ductal Carcinoma In Situ

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free